Rare Germline Variants in Immune and Drug Target Genes Among Cancer Exceptional Responders

Germline WGS comparison of 51 cancer exceptional responders (NEER) vs 414 PCAWG patients — identification of rare germline variants in immune and drug-target genes enriched in exceptional responders

This study explores the germline profile of 51 cancer exceptional responders via WGS compared to 414 PCAWG patients. Germline variants in immune genes (CCL26, GPRC5D) and drug-target genes are enriched in responders. IRX3 emerges as potentially protective, while OR6B2 is associated with poor lung cancer survival. Germline variants in DNA repair and cisplatin/doxorubicin target genes are also enriched in this subgroup.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

The concept of germline profiling of exceptional responders is innovative and opens an avenue for predictive personalized medicine. However, the sample size (n=51 ERs) and exploratory design strongly limit the scope, and associations with IRX3 or OR6B2 are very preliminary. To be considered a hypothesis-generating study pending prospective validation.

Clinical impact: 2/3 · Evidence strength: 1/3 · Novelty: 2/2 · Sample size: 0/1 · Journal quality: 0/1 · Preprint: -1 → Total: 4/10